Home | PHARMAC
Home | PHARMAC
  • Website
  • Application Tracker
  • Schedule
  • About PHARMAC
    • About PHARMAC
    • Your guide to PHARMAC
    • Our history
    • Our people
    • Expert advice
    • PHARMAC's performance
    • Operating policies and procedures
    • Year in review 2018
    • Strategies
  • Medicines
    • Medicines
    • How medicines are funded
    • Medicines information
    • My medicine or medical device has changed
    • Your health
    • Hospital pharmaceuticals
    • New medicines – from development to funding
    • Equity
  • Hospital devices
    • Hospital devices
    • What's happening in each category?
    • PHARMAC's approach to hospital devices
    • Device Advice
    • PHARMAC medical devices forums 2017
  • News
  • Te Whaioranga
    • Te Whaioranga
    • Te Whaioranga 2013 - 2023: Māori Responsiveness Strategy
    • Whānau Ora
    • He Rongoā Pai, He Oranga Whānau
    • One Heart Many Lives
    • Scholarships
    • Hauora Arotahi - Māori health areas of focus
    • Māori Responsiveness Team
  • Pacific
    • Pacific
    • Pacific responsiveness strategy
    • Pacific action plan
  • Tools & resources
    • Tools & resources
    • Pharmaceutical Schedule
    • Annual Procurement Plan
    • Forms
    • Research
    • Print and PDF resources
    • Glossary
    • PHARMAC labelling preferences for prescription pharmaceuticals
  • Information for…
  1. Medicines /
  2. New medicines /
  3. Clinical trials

See more about this section

Medicines

  • How medicines are funded
  • Medicines information
  • My medicine or medical device has changed
  • Your health
  • Hospital pharmaceuticals
  • New medicines
    • Clinical trials
    • New cancer treatments
    • Early access schemes
    • International medicine pricing
  • Equity

Medicines

  • How medicines are funded
  • Medicines information
  • My medicine or medical device has changed
  • Your health
  • Hospital pharmaceuticals
  • New medicines
    • Clinical trials
    • New cancer treatments
    • Early access schemes
    • International medicine pricing
  • Equity

Clinical trials

In order to fully understand the benefits and risks of a new medicine a pharmaceutical company must undertake a range of clinical trials as part of its clinical development programme for a new medicine.

Clinical development programmes usually comprise four phases, with each phase conducted consecutively using the information collected in the previous phase. These phases, their primary purpose and typical clinical trial designs are outlined in the table below:

Clinical development phasePrimary purposeTypical clinical trial designTypical number of trial participants
Phase I (1) To test for preliminary safety and establish the optimal dose of the new medicine Small numbers of healthy volunteers or sometimes patients. Initially low doses of the new medicine are given with doses increased overtime. 20-100
Phase II (2) To test for safety and preliminary effectiveness of the new medicine in patients All patients given the new medicine at the optimal dose. 100-300
Phase III (3) To establish the safety and efficacy of the new medicine compared with the current medicine normally used in patients.

It is typically expected that there be at least two successful Phase III trials conducted.
Half of the patients are given the new medicine (investigational group) at the optimal dose, with the other half given placebo and/or the current standard medicine (comparator or control group). Patients are randomly assigned to one of the two treatment arms.

They are commonly known as Randomised controlled trials (RCTs)

Sometimes these trials are ‘blinded’ (meaning that neither the patient nor their doctor knows what medicine each patient is getting), or ‘open-label’ (meaning that both the patient and their doctor know what treatment they are getting). Blinded trials are preferred as they avoid bias in assessing outcomes
300-3000 or more depending on the disease
Phase IV (4) To monitor for safety concerns in the public after the new medicine has been approved by the regulator for sale Spontaneous reporting of safety issued by doctors when they use the treatment in any of their patients NA

The reliability of the results obtained from clinical trials is highly dependent on their design and conduct. Various aspects of clinical trial design and conduct can have a substantial negative effect on the reliability and relevance of clinical trial results, for example:

  • short follow-up of patients
  • use of early (so called ‘surrogate’) measures of benefit
  • multiple analyses of the same trial
  • cross over of patients from the control group to the investigational group
  • enrolling patients that are different to those that will be treated in normal practice
  • using different doses of the medicine than will be used in practice.

Last updated: 29 March 2016

About this site

  • Sitemap
  • Copyright
  • Disclaimer
  • Privacy statement
  • This site is operated by PHARMAC, the Pharmaceutical Management Agency.

Contact

  • Contact us
  • Twitter - PHARMACnz
  • Facebook - PHARMACnz
  • YouTube - PHARMACgovtnz
  • LinkedIn - Pharmaceutical Management Agency (PHARMAC)
  • Careers
  • Newsfeed

Back to top

New Zealand Government